NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALKS stock has increased by 2.3% and is now trading at $16.62. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) issued its earnings results on Wednesday, April, 29th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.07. The business had revenue of $246.20 million for the quarter, compared to analysts' expectations of $230.53 million. Alkermes had a positive return on equity of 4.99% and a negative net margin of 11.63%. The business's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) EPS. View Alkermes' earnings history.

12 brokerages have issued 1 year price targets for Alkermes' shares. Their forecasts range from $16.00 to $28.00. On average, they expect Alkermes' share price to reach $21.17 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price. View analysts' price targets for Alkermes.

Media coverage about ALKS stock has been trending very positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alkermes earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAlkermes.

Alkermes saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,290,000 shares, an increase of 16.6% from the April 15th total of 7,970,000 shares. Based on an average trading volume of 2,020,000 shares, the short-interest ratio is currently 4.6 days. Currently, 5.9% of the shares of the company are sold short. View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (13.82%), Primecap Management Co. CA (5.67%), BlackRock Inc. (5.55%), Sarissa Capital Management LP (4.53%), Camber Capital Management LP (3.81%) and State Street Corp (2.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Two Sigma Investments LP, BlackRock Inc., Deutsche Bank AG, Engineers Gate Manager LP, Rafferty Asset Management LLC, Spark Investment Management LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops. View insider buying and selling activity for Alkermes.

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Maverick Capital Ltd., Camber Capital Management LP, BNP Paribas Arbitrage SA, Invesco Ltd., Atom Investors LP, UBS Group AG, and Krensavage Asset Management LLC. View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $16.62.

Alkermes has a market capitalization of $2.64 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]